Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
Retrieved on:
Friday, March 25, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Birth, Risk, Hepatitis B virus, Cancer, Rash, SMN2, Shingles, Liver failure, Vaccination, Death, Simplex, SMA, Spinal muscular atrophy, Disability, Fertility, Confusion, Adult, Skin, Central nervous system, Vaccine, CNS, Pregnancy, Pachydactylus labialis, Fever, Antibody, Focal neurologic signs, Patient, Infection, Health, Medicine, Thought, Pain, Breast milk, Immune system, Mouth, PML, Vitamin, Progressive multifocal leukoencephalopathy, MS, Hepatitis B, Encephalitis, Protein, Male, Pharmacy, Chills, Weakness, Neuron, Movement, HBV, SMN, Liver, Cover My Eyes (Pain and Heaven), FDA, Breast cancer, Water, Medical device, Health insurance, Birth control, Dietary supplement, Risk management, Pharmaceutical industry, Ocrelizumab, Risdiplam, Risdiplam, OCREVUS® (OCRELIZUMAB), EVRYSDI™ (RISDIPLAM), ENSPRYNGTM (SATRALIZUMAB), ENSPRYNGTM, GENENTECH IN NEUROSCIENCE, GENENTECH
If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
Key Points:
- If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
- Signs of infection can happen during treatment or after you have received your last dose of Ocrevus.
- Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with Ocrevus treatment in clinical trials, PML may happen with Ocrevus.
- Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.